Most-cited are based on citations from 2021 ~ 2023.

Guideline KASL clinical practice guidelines: Management of nonalcoholic fatty liver disease

Seong Hee Kang, Hye Won Lee, Jeong-Ju Yoo, Yuri Cho, Seung Up Kim, Tae Hee Lee, Byoung Kuk Jang, Sang Gyune Kim, Sang Bong Ahn, Haeryoung Kim, Dae Won Jun, Joon-Il Choi, Do Seon Song, Won Kim, Soung Won Jeong, Moon Young Kim, Hong Koh, Sujin Jeong, Jin-Woo Lee, Yong Kyun Cho

Clin Mol Hepatol. 2021;27(3):363-401.

Reviews From nonalcoholic fatty liver disease to metabolic-associated fatty liver disease: Big wave or ripple?

Seong Hee Kang, Yuri Cho, Soung Won Jeong, Seung Up Kim, Jin-Woo Lee

Clin Mol Hepatol. 2021;27(2):257-269.

Original Articles Lactobacillus attenuates progression of nonalcoholic fatty liver disease by lowering cholesterol and steatosis

Na Young Lee, Min Jea Shin, Gi Soo Youn, Sang Jun Yoon, Ye Rin Choi, Hyeong Seop Kim, Haripriya Gupta, Sang Hak Han, Byoung Kook Kim, Do Yup Lee, Tae Sik Park, Hotaik Sung, Byung Yong Kim, Ki Tae Suk

Clin Mol Hepatol. 2021;27(1):110-124.

Obesity and the risk of primary liver cancer: A systematic review and meta-analysis

Won Sohn, Hyun Woong Lee, Sangheun Lee, Jin Hong Lim, Min Woo Lee, Chan Hyuk Park, Seung Kew Yoon

Clin Mol Hepatol. 2021;27(1):157-174.

Reviews The development of mesenchymal stem cell therapy in the present, and the perspective of cell-free therapy in the future

Yusuke Watanabe, Atsunori Tsuchiya, Shuji Terai

Clin Mol Hepatol. 2021;27(1):70-80.

The role of the gut microbiome and diet in the pathogenesis of non-alcoholic fatty liver disease

Erica Jennison, Christopher D. Byrne

Clin Mol Hepatol. 2021;27(1):22-43.

Current understanding of primary biliary cholangitis

Atsushi Tanaka

Clin Mol Hepatol. 2021;27(1):1-21.

Recent updates on the management of autoimmune hepatitis

Atsumasa Komori

Clin Mol Hepatol. 2021;27(1):58-69.

Original Articles Outcomes after liver transplantation in Korea: Incidence and risk factors from Korean transplantation registry

Jong Man Kim, Deok Gie Kim, Jihyun Kim, Keunsung Lee, Kwang-Woong Lee, Je Ho Ryu, Bong-Wan Kim, Dong Lak Choi, Young Kyoung You, Dong-Sik Kim, Yang Won Nah, Koo Jeong Kang, Jai Young Cho, Geun Hong, Hee Chul Yu, Ju Ik Moon, Dongho Choi, Shin Hwang, Myoung Soo Kim

Clin Mol Hepatol. 2021;27(3):451-462.

Reviews Entecavir versus tenofovir in patients with chronic hepatitis B: Enemies or partners in the prevention of hepatocellular carcinoma

Sung Won Lee, Jonggi Choi, Seung Up Kim, Young-Suk Lim

Clin Mol Hepatol. 2021;27(3):402-412.

Evaluation and management of extrahepatic manifestations of nonalcoholic fatty liver disease

Karn Wijarnpreecha, Elizabeth S. Aby, Aijaz Ahmed, Donghee Kim

Clin Mol Hepatol. 2021;27(2):221-235.

Original Articles Non-alcoholic fatty liver disease increases risk of carotid atherosclerosis and ischemic stroke: An updated meta-analysis with 135,602 individuals

Ansel Shao Pin Tang, Kai En Chan, Jingxuan Quek, Jieling Xiao, Phoebe Tay, Margaret Teng, Keng Siang Lee, Snow Yunni Lin, May Zin Myint, Benjamin Tan, Vijay K Sharma, Darren Jun Hao Tan, Wen Hui Lim, Apichat Kaewdech, Daniel Huang, Nicholas WS Chew, Mohammad Shadab Siddiqui, Arun J Sanyal, Mark Muthiah, Cheng Han Ng

Clin Mol Hepatol. 2022;28(3):483-496.

Reviews Optimizing the management of intermediate-stage hepatocellular carcinoma: Current trends and prospects

Takuji Torimura, Hideki Iwamoto

Clin Mol Hepatol. 2021;27(2):236-245.

Updates in the quantitative assessment of liver fibrosis for nonalcoholic fatty liver disease: Histological perspective

Gwyneth Soon, Aileen Wee

Clin Mol Hepatol. 2021;27(1):44-57.

MAFLD enhances clinical practice for liver disease in the Asia-Pacific region

Takumi Kawaguchi, Tsubasa Tsutsumi, Dan Nakano, Mohammed Eslam, Jacob George, Takuji Torimura

Clin Mol Hepatol. 2022;28(2):150-163.

Original Articles The effect of diabetes and prediabetes on the prevalence, complications and mortality in nonalcoholic fatty liver disease

Cheng Han Ng, Kai En Chan, Yip Han Chin, Rebecca Wenling Zeng, Pei Chen Tsai, Wen Hui Lim, Darren Jun Hao Tan, Chin Meng Khoo, Lay Hoon Goh, Zheng Jye Ling, Anand Kulkarni, Lung-Yi Loey Mak, Daniel Q Huang, Mark Chan, Nicholas WS Chew, Mohammad Shadab Siddiqui, Arun J. Sanyal, Mark Muthiah

Clin Mol Hepatol. 2022;28(3):565-574.

Scaling up the in-hospital hepatitis C virus care cascade in Taiwan

Chung-Feng Huang, Pey-Fang Wu, Ming-Lun Yeh, Ching-I Huang, Po-Cheng Liang, Cheng-Ting Hsu, Po-Yao Hsu, Hung-Yin Liu, Ying-Chou Huang, Zu-Yau Lin, Shinn-Cherng Chen, Jee-Fu Huang, Chia-Yen Dai, Wan-Long Chuang, Ming-Lung Yu

Clin Mol Hepatol. 2021;27(1):136-143.

Reviews Nonalcoholic fatty liver disease versus metabolic-associated fatty liver disease: Prevalence, outcomes and implications of a change in name

Cheng Han Ng, Daniel Q. Huang, Mindie H. Nguyen

Clin Mol Hepatol. 2022;28(4):790-801.

Three heads are better than two: Hepatitis B core-related antigen as a new predictor of hepatitis B virus-related hepatocellular carcinoma

Jer-Wei Wu, Jia-Horng Kao, Tai-Chung Tseng

Clin Mol Hepatol. 2021;27(4):524-534.

Recent advances in nonalcoholic fatty liver disease metabolomics

Hwi Young Kim

Clin Mol Hepatol. 2021;27(4):553-559.

Original Articles Persistence of intrahepatic hepatitis B virus DNA integration in patients developing hepatocellular carcinoma after hepatitis B surface antigen seroclearance

Jeong Won Jang, Jin Seoub Kim, Hye Seon Kim, Kwon Yong Tak, Heechul Nam, Pil Soo Sung, Si Hyun Bae, Jong Young Choi, Seung Kew Yoon, Lewis R. Roberts

Clin Mol Hepatol. 2021;27(1):207-218.

Reviews Toward a complete cure for chronic hepatitis B: Novel therapeutic targets for hepatitis B virus

Sun Woong Kim, Jun Sik Yoon, Minjong Lee, Yuri Cho

Clin Mol Hepatol. 2022;28(1):17-30.

Changes in the epidemiology and management of bacterial infections in cirrhosis

Salvatore Piano, Marta Tonon, Paolo Angeli

Clin Mol Hepatol. 2021;27(3):437-445.

RNA interference as a novel treatment strategy for chronic hepatitis B infection

Rex Wan-Hin Hui, Lung-Yi Mak, Wai-Kay Seto, Man-Fung Yuen

Clin Mol Hepatol. 2022;28(3):408-424.

Anti-fibrotic treatments for chronic liver diseases: The present and the future

Naoshi Odagiri, Tsutomu Matsubara, Misako Sato-Matsubara, Hideki Fujii, Masaru Enomoto, Norifumi Kawada

Clin Mol Hepatol. 2021;27(3):413-424.

Original Articles Loss-of-function HSD17B13 variants, non-alcoholic steatohepatitis and adverse liver outcomes: Results from a multi-ethnic Asian cohort

Yi-Wen Ting, Amanda Shen-Yee Kong, Shamsul Mohd Zain, Wah-Kheong Chan, Hwa-Li Tan, Zahurin Mohamed, Yuh-Fen Pung, Rosmawati Mohamed

Clin Mol Hepatol. 2021;27(3):486-498.

Radiation-induced abscopal effect and its enhancement by programmed cell death 1 blockade in the hepatocellular carcinoma: A murine model study

Gyu Sang Yoo, Won-Gyun Ahn, Shin-Yeong Kim, Wonseok Kang, Changhoon Choi, Hee Chul Park

Clin Mol Hepatol. 2021;27(1):144-156.

Impact of everolimus on survival after liver transplantation for hepatocellular carcinoma

Incheon Kang, Jae Geun Lee, Sung Hoon Choi, Hyun Jeong Kim, Dai Hoon Han, Gi Hong Choi, Myoung Soo Kim, Jin Sub Choi, Soon Il Kim, Dong Jin Joo

Clin Mol Hepatol. 2021;27(4):589-602.

Snapshot Hepatocellular carcinoma statistics in South Korea

Young Eun Chon, Soung Won Jeong, Dae Won Jun

Clin Mol Hepatol. 2021;27(3):512-514.

Reviews Crosstalk between tumor-associated macrophages and neighboring cells in hepatocellular carcinoma

Pil Soo Sung

Clin Mol Hepatol. 2022;28(3):333-350.